Trends in first-line antiretroviral therapy in Asia: Results from the treat Asia HIV Observational Database

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Boettiger, David Charles ^a   Kerr, Stephen ^a,b   Ditangco, Rossana ^c   Merati, Tuti Parwati ^d   Pham, Thuy Thi Thanh ^e   Chaiwarith, Romanee ^f   Kiertiburanakul, Sasisopin ^g   Li, Chung Ki Patrick ^h   Kumarasamy, Nagalingeswaran ⁱ   Vonthanak, Saphonn ^j   Lee, Christopher ^k   Van Kinh, Nguyen ^l   Pujari, Sanjay ^m   Wong, Wing Wai ⁿ   Kamarulzaman, Adeeba ^o   Zhang, Fujie ^p   Yunihastuti, Evy ^q   Choi, Jun Yong ^r   Oka, Shinichi ^s   Ng, Oon Tek ^t   Kantipong, Pacharee ^u   Mustafa, Mahiran ^v   Ratanasuwan, Winai ^w   Sohn, Annette ^x   Law, Matthew ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^d UDAYANA UNIVERSITY   (Indonesia)

^e BACH MAI HOSPITAL   (Viet Nam)

^f Research Institute for Health Sciences   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h QUEEN ELIZABETH HOSPITAL   (Hong Kong)

ⁱ YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^j Dermatology and STD   (Cambodia)

^k HOSPITAL SUNGAI BULOH   (Malaysia)

^l National Hospital of Tropical Diseases   (Viet Nam)

^m Institute of Infectious Diseases   (India)

ⁿ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^o UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^p CAPITAL MEDICAL UNIVERSITY   (China)

^q UNIVERSITY OF INDONESIA   (Indonesia)

^r Yonsei University College of Medicine   (South Korea)

^s NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^t TAN TOCK SENG HOSPITAL   (Singapore)

^u CHIANGRAI PRACHANUKROH HOSPITAL   (Thailand)

^v Hospital Raja Perempuan Zainab II   (Malaysia)

^w MAHIDOL UNIVERSITY   (Thailand)

^x Foundation for AIDS Research   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGING; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; ASIA; DATA BASE; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIMARY HEALTH CARE; RISK FACTOR; SEX DIFFERENCE; TREATMENT FAILURE; TREND STUDY; ADVERSE DRUG REACTION; ADVERSE EFFECTS; CLASSIFICATION; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; PATHOLOGY; PROCEDURES; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; DIDEOXYNUCLEOSIDES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 84906982770     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106525     Document Type: Article

References (26)

1. WHO ART Guidelines Committee (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach - June 2013. Available: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html [Accessed 2014 January 3].
2. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308:387-402.
3. Williams I, Churchill D, Anderson J, Boffito M, Bower M, et al. (2012) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 13 Suppl 2:1-85.
4. WHO ART Guidelines Committee (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. Available: http://www.who.int/hiv/pub/arv/adult2010/en/index.html [Accessed 2013 May 15].
5. WHO ART Guidelines Committee (2006) Antiretroviral therapy for HIV infection in adults and adolescents - Recommendations for a public health approach - 2006 revision. Available: http://www.who.int/hiv/pub/arv/adult/en/[Accessed 2013 November 5].
6. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N (2010) Efavirenz or nevirapine in three-drug combination therapy with two nucleosidereverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev: CD004246.
7. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, et al. (2013) Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis 13:303-312.
8. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, et al. (2013) Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 27:1403-1412.
9. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R (2006) Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada. AIDS Patient Care STDS 20:245-257.
10. Geng EH, Hunt PW, Diero LO, Kimaiyo S, Somi GR, et al. (2011) Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc 14:46.
11. Jimenez-Nacher I, Garcia B, Barreiro P, Rodriguez-Novoa S, Morello J, et al. (2008) Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 62:816-822.
12. McConnell MS, Byers RH, Frederick T, Peters VB, Dominguez KL, et al. (2005) Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr 38:488-494.
13. Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, et al. (2011) Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 41:43-54.
14. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, et al. (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 38:174-179.
15. Palmisano L, Vella S (2011) A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita 47:44-48.
16. Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miro O, et al. (2007) The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 12:407-415.
17. Ribera E, Paradineiro JC, Curran A, Sauleda S, Garcia-Arumi E, et al. (2008) Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 9:407-417.
18. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, et al. (2008) Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials 9:324-336.
19. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, et al. (2007) Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 44:1484-1492.
20. Lichterfeld M, Wohrmann A, Schmeisser N, Fatkenheuer G, Salzberger B, et al. (2003) Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy. Eur J Med Res 8:56-60.
21. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, et al. (2008) Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372:646-655.
22. UNAIDS (2012) UNAIDS Report on the Global AIDS Epidemic 2012. Available: http://www.unaids.org/en/resources/publications/2012/name,76121,en.asp [Accessed 2013 May 15].
23. Bannister WP, Kirk O, Gatell JM, Knysz B, Viard JP, et al. (2006) Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 42:229-237.
24. Gonzalez-Serna A, Chan K, Yip B, Chau W, McGovern R, et al. (2014) Temporal trends in the discontinuation of first-line antiretroviral therapy. J Antimicrob Chemother.
25. Looby SE, Shifren J, Corless I, Rope A, Pedersen MC, et al. (2014) Increased hot flash severity and related interference in perimenopausal human immunodeficiency virus-infected women. Menopause 21:403-409.
26. Wright S, Boyd MA, Yunihastuti E, Law M, Sirisanthana T, et al. (2013) Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS One 8:e64902.